STOCK TITAN

Bolt Biotherapeutics, Inc. - BOLT STOCK NEWS

Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.

Bolt Biotherapeutics, Inc. (BOLT) is a clinical-stage biopharmaceutical company specializing in novel immunotherapies for cancer treatment. Originating from Dr. Engleman's lab at Stanford University, the company leverages groundbreaking technology to develop tumor-targeted therapies, capitalizing on the combined power of the innate and adaptive immune systems. Backed by top-tier life sciences investors, Bolt is on a promising growth trajectory, dedicated to bringing innovative and curative therapies to patients.

The company’s proprietary Boltbody™ ISAC (Immune-Stimulating Antibody Conjugate) platform is the cornerstone of its therapeutic pipeline, which includes candidates like BDC-1001 and BDC-3042. This platform merges tumor-targeting antibodies with immune-stimulating linker-payloads designed to reprogram the tumor microenvironment, fostering a robust anti-cancer response.

BDC-1001 targets HER2-positive cancers and has shown durable clinical responses and a favorable safety profile in Phase 1 trials. Notably, the FDA granted Orphan Drug Designation to BDC-1001 for gastric cancer treatment, underlining its potential to address unmet medical needs. Phase 2 trials are underway for various cancers, including breast, colorectal, and endometrial cancers.

BDC-3042 targets Dectin-2, a receptor expressed by tumor-associated macrophages (TAMs), and aims to convert these cells from tumor-supportive to tumor-destructive. Having received FDA clearance for its Investigational New Drug (IND) application, BDC-3042 is set to enter Phase 1 trials.

Bolt's pipeline also includes multiple Boltbody ISAC collaboration programs with leading biopharmaceutical companies, further validating its platform technology. The company’s financial health is robust, with strategic plans to fund ongoing and future clinical programs.

For more information, visit Bolt Biotherapeutics, Inc. website.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.27%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.07%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags

FAQ

What is Bolt Biotherapeutics, Inc.?

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment.

What is the Boltbody™ ISAC platform?

The Boltbody™ ISAC platform combines tumor-targeting antibodies with immune-stimulating linker-payloads to reprogram the tumor microenvironment and generate an anti-cancer response.

What are BDC-1001 and BDC-3042?

BDC-1001 is a HER2-targeting ISAC in Phase 2 trials for various cancers, and BDC-3042 is a myeloid-modulating antibody targeting Dectin-2, entering Phase 1 trials.

What recent achievements has Bolt Biotherapeutics made?

Recent achievements include FDA Orphan Drug Designation for BDC-1001 for gastric cancer and positive Phase 1 results for BDC-1001.

Who backs Bolt Biotherapeutics?

Bolt Biotherapeutics is backed by top-tier life sciences investors and originated from Dr. Engleman’s lab at Stanford University.

What is the significance of Orphan Drug Designation for BDC-1001?

The Orphan Drug Designation for BDC-1001 highlights its potential to address unmet needs in treating rare cancers like gastric cancer.

What are the goals of the BDC-3042 program?

The goal of the BDC-3042 program is to repolarize tumor-associated macrophages from tumor-supportive to tumor-destructive cells.

What partnerships does Bolt Biotherapeutics have?

Bolt Biotherapeutics has multiple Boltbody ISAC collaboration programs with leading biopharmaceutical companies to advance its technology.

How is Bolt Biotherapeutics advancing its clinical programs?

Bolt Biotherapeutics continues to progress its clinical programs, with Phase 2 trials for BDC-1001 and upcoming Phase 1 trials for BDC-3042.

Where can I find more information about Bolt Biotherapeutics?

For more information, visit Bolt Biotherapeutics' official website at https://www.boltbio.com/.

Bolt Biotherapeutics, Inc.

Nasdaq:BOLT

BOLT Rankings

BOLT Stock Data

27.87M
38.13M
3.47%
64.19%
4.86%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY